Wahl Andrew O, Rademaker Alfred, Kiel Krystyna D, Jones Ellen L, Marks Lawrence B, Croog Victoria, McCormick Beryl M, Hirsch Arica, Karkar Ami, Motwani Sabin B, Tereffe Welela, Yu Tse-Kuan, Sher David, Silverstein Joshua, Kachnic Lisa A, Kesslering Christy, Freedman Gary M, Small William
Department of Radiation Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):477-84. doi: 10.1016/j.ijrobp.2007.06.035. Epub 2007 Sep 14.
To review the toxicity and clinical outcomes for patients who underwent repeat chest wall or breast irradiation (RT) after local recurrence.
Between 1993 and 2005, 81 patients underwent repeat RT of the breast or chest wall for locally recurrent breast cancer at eight institutions. The median dose of the first course of RT was 60 Gy and was 48 Gy for the second course. The median total radiation dose was 106 Gy (range, 74.4-137.5 Gy). At the second RT course, 20% received twice-daily RT, 54% were treated with concurrent hyperthermia, and 54% received concurrent chemotherapy.
The median follow-up from the second RT course was 12 months (range, 1-144 months). Four patients developed late Grade 3 or 4 toxicity. However, 25 patients had follow-up >20 months, and no late Grade 3 or 4 toxicities were noted. No treatment-related deaths occurred. The development of Grade 3 or 4 late toxicity was not associated with any repeat RT variables. The overall complete response rate was 57%. No repeat RT parameters were associated with an improved complete response rate, although a trend was noted for an improved complete response with the addition of hyperthermia that was close to reaching statistical significance (67% vs. 39%, p = 0.08). The 1-year local disease-free survival rate for patients with gross disease was 53% compared with 100% for those without gross disease (p < 0.0001).
The results of our study have shown that repeat RT of the chest wall for patients with locally recurrent breast cancer is feasible, because it is associated with acceptable acute and late morbidity and encouraging local response rates.
回顾局部复发后接受重复胸壁或乳腺放疗(RT)患者的毒性反应及临床结局。
1993年至2005年期间,8家机构的81例患者因局部复发性乳腺癌接受了乳腺或胸壁的重复放疗。首次放疗疗程的中位剂量为60 Gy,第二次疗程为48 Gy。中位总辐射剂量为106 Gy(范围74.4 - 137.5 Gy)。在第二次放疗疗程中,20%的患者接受每日两次放疗,54%的患者接受同期热疗,54%的患者接受同期化疗。
第二次放疗疗程后的中位随访时间为12个月(范围1 - 144个月)。4例患者出现晚期3级或4级毒性反应。然而,25例患者的随访时间>20个月,未观察到晚期3级或4级毒性反应。未发生与治疗相关的死亡。3级或4级晚期毒性反应的发生与任何重复放疗变量均无关。总体完全缓解率为57%。尽管添加热疗后完全缓解率有改善趋势且接近具有统计学意义(67%对39%,p = 0.08),但没有重复放疗参数与更高的完全缓解率相关。有肉眼可见病变患者的1年局部无病生存率为53%,而无肉眼可见病变患者为100%(p < 0.0001)。
我们的研究结果表明,局部复发性乳腺癌患者进行胸壁重复放疗是可行的,因为其急性和晚期发病率可接受,且局部反应率令人鼓舞。